BALYASNY ASSET MANAGEMENT L.P. - CYTOMX THERAPEUTICS INC ownership

CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 99 filers reported holding CYTOMX THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
BALYASNY ASSET MANAGEMENT L.P. ownership history of CYTOMX THERAPEUTICS INC
ValueSharesWeighting
Q4 2022$55,680
+165.1%
34,800
+135.2%
0.00%
Q3 2022$21,000
-30.0%
14,794
-10.6%
0.00%
Q2 2022$30,000
-53.1%
16,552
+64.5%
0.00%
Q2 2021$64,000
-83.2%
10,059
-39.5%
0.00%
-100.0%
Q2 2018$380,000
-13.6%
16,632
+7.5%
0.00%0.0%
Q1 2018$440,00015,4750.00%
Other shareholders
CYTOMX THERAPEUTICS INC shareholders Q2 2022
NameSharesValueWeighting ↓
GREAT POINT PARTNERS LLC 1,500,000$7,635,0001.78%
Altium Capital Management LP 1,233,642$6,279,0001.65%
RA Capital Management 3,500,000$17,815,0000.25%
Soleus Capital Management, L.P. 261,050$1,329,0000.21%
Affinity Asset Advisors, LLC 125,000$636,0000.16%
PLATINUM INVESTMENT MANAGEMENT LTD 1,078,103$5,488,0000.16%
Point72 Asset Management, L.P. 6,303,025$32,082,0000.14%
GSA CAPITAL PARTNERS LLP 249,146$1,268,0000.13%
Candriam S.C.A. 3,305,940$16,826,0000.11%
RTW INVESTMENTS, LP 1,400,939$7,131,0000.11%
View complete list of CYTOMX THERAPEUTICS INC shareholders